📊 CUE Key Takeaways
Is Cue Biopharma, Inc. (CUE) a Good Investment?
Cue Biopharma is an early-stage biotech company with promising 7793% revenue growth and improving EPS, but faces critical cash runway constraints. With $16.4M cash and -$11.1M annual FCF burn, the company has approximately 18 months of operating capital before requiring additional financing, creating binary execution risk.
Cue Biopharma shows a sharp revenue increase, but profitability quality remains weak because operating and net margins are still deeply negative and free cash flow remains materially negative. The balance sheet is relatively clean with no long-term debt and solid near-term liquidity, but continued cash burn and negative returns on assets and equity suggest the business model is not yet financially self-sustaining.
Cue Biopharma, Inc. Key Strengths (CUE)
- Zero debt with clean balance sheet (Debt/Equity: 0.00x); no debt service burden
- Exceptional liquidity position with 3.57x current and quick ratios; can easily cover near-term obligations
- Dramatic 7793.6% YoY revenue growth and improving diluted EPS (61.1% YoY improvement) suggest early commercialization traction
- Reasonable stockholders' equity base of $21.6M provides solvency cushion
- Strong liquidity with $27.14M in cash and a 2.74x current ratio
- No long-term debt, which reduces balance-sheet risk
- Revenue growth was exceptionally strong year over year, indicating potential partnership or milestone-driven inflows
CUE Stock Risks: Cue Biopharma, Inc. Investment Risks
- Critical cash runway of ~18 months at current -$11.1M FCF burn rate; requires near-term funding or profitability achievement
- Deeply unprofitable with -91.1% net margin and -94.1% operating margin; no visible path to profitability in near term
- Early-stage biotech with $5.7M revenue base faces high binary clinical and commercial execution risk; limited margin for error
- Negative operating cash flow of -$10.9M indicates operations are cash-consumptive and company is not self-sustaining
- Future funding likely to cause significant shareholder dilution to extend runway beyond 18-month horizon
- Operating and net margins remain near -97%, showing severe unprofitability
- Free cash flow of -$21.86M indicates continued heavy cash burn
- Revenue growth quality may be weak or non-recurring if driven by milestone or collaboration payments rather than durable commercialization
Key Metrics to Watch
- Quarterly cash burn rate and estimated cash runway; any extension of operating expenses increases dilution risk
- Revenue growth sustainability and product commercialization progress; growth trajectory determines cash consumption period
- Clinical trial outcomes and regulatory milestone achievements; critical for demonstrating value in future funding rounds
- Operating expense management and cost control; ability to extend cash runway without revenue growth
- Capital raise timing, size, and dilution impact; necessity and terms of future financing indicate investor confidence
- Quarterly operating cash burn relative to cash balance
- Sustainability and composition of revenue growth versus recurring operating losses
Cue Biopharma, Inc. (CUE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.57x current ratio provides a solid financial cushion.
CUE Profit Margin, ROE & Profitability Analysis
CUE vs Healthcare Sector: How Cue Biopharma, Inc. Compares
How Cue Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cue Biopharma, Inc. Stock Overvalued? CUE Valuation Analysis 2026
Based on fundamental analysis, Cue Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cue Biopharma, Inc. Balance Sheet: CUE Debt, Cash & Liquidity
CUE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cue Biopharma, Inc.'s revenue has grown significantly by 84% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.72 indicates the company is currently unprofitable.
CUE Revenue Growth, EPS Growth & YoY Performance
CUE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $421.0K | -$5.2M | $-1.08 |
| Q3 2025 | $2.1M | -$7.4M | $-0.07 |
| Q2 2025 | $2.7M | -$8.5M | $-0.09 |
| Q1 2025 | $421.0K | -$12.3M | $-0.17 |
| Q3 2024 | $2.1M | -$8.7M | $-0.17 |
| Q2 2024 | $1.4M | -$10.2M | $-0.20 |
| Q1 2024 | $187.0K | -$12.3M | $-0.25 |
| Q3 2023 | $68.0K | -$11.0M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cue Biopharma, Inc. Dividends, Buybacks & Capital Allocation
CUE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cue Biopharma, Inc. (CIK: 0001645460)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CUE
What is the AI rating for CUE?
Cue Biopharma, Inc. (CUE) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CUE's key strengths?
Claude: Zero debt with clean balance sheet (Debt/Equity: 0.00x); no debt service burden. Exceptional liquidity position with 3.57x current and quick ratios; can easily cover near-term obligations. ChatGPT: Strong liquidity with $27.14M in cash and a 2.74x current ratio. No long-term debt, which reduces balance-sheet risk.
What are the risks of investing in CUE?
Claude: Critical cash runway of ~18 months at current -$11.1M FCF burn rate; requires near-term funding or profitability achievement. Deeply unprofitable with -91.1% net margin and -94.1% operating margin; no visible path to profitability in near term. ChatGPT: Operating and net margins remain near -97%, showing severe unprofitability. Free cash flow of -$21.86M indicates continued heavy cash burn.
What is CUE's revenue and growth?
Cue Biopharma, Inc. reported revenue of $5.7M.
Does CUE pay dividends?
Cue Biopharma, Inc. does not currently pay dividends.
Where can I find CUE SEC filings?
Official SEC filings for Cue Biopharma, Inc. (CIK: 0001645460) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CUE's EPS?
Cue Biopharma, Inc. has a diluted EPS of $-1.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CUE's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cue Biopharma, Inc. has a C grade with 67% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CUE stock overvalued or undervalued?
Valuation metrics for CUE: ROE of -24.0% (sector avg: 15%), net margin of -91.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CUE's AI grade for 2026?
Our dual AI analysis gives Cue Biopharma, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CUE's free cash flow?
Cue Biopharma, Inc.'s operating cash flow is $-10.9M, with capital expenditures of $121.0K. FCF margin is -194.6%.
How does CUE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -91.1% (avg: 12%), ROE -24.0% (avg: 15%), current ratio 3.57 (avg: 2).